This is an automatically translated article.
Lukatab is a drug used in the prevention and treatment of chronic bronchial asthma, seasonal and year-round allergic rhinitis in adults and children over 15 years of age. Find out more about the effects and dosage of the drug before using it.1. What does Lukatab do?
Lukatab contains the main ingredient Montelukast (as Montelukast sodium) 10mg. This is an active ingredient that has the ability to inhibit leukotrienes (substances released by the body if inhaled allergens such as pollen) help bring about tightening and inflammation of the muscles around the airways. As a result, Lukatab has the ability to improve inflammation in the airways, making breathing easier.
2. Indications and contraindications to the drug Lukatab
2.1. Indications Lukatab is indicated for use in the following cases:
Prophylaxis or adjunctive treatment of chronic bronchial asthma in adults and children aged 15 years and older, including asthma symptoms, aspirin-sensitive asthma and prevention of asthma. Prevention of exercise-induced bronchospasm. Relieving symptoms of allergic rhinitis occurring during the day or at night (Including seasonal allergic rhinitis and perennial allergic rhinitis). 2.2. Contraindications Do not use Lukatab in patients with hypersensitivity to the Montelukast component of the drug.
3. Dosage and how to use Lukatab
Use the drug with a dose of 1 tablet / time / day on an empty stomach or after a full meal. How to use Lukatab refer to the following:
For asthmatics, take the medicine in the evening. For patients with allergic rhinitis, the duration of medication can depend on the needs of each patient. For patients with both asthma and allergic rhinitis, the drug should be used at night before bed.
4. Lukatab side effects
During the use of Lukatab, patients may experience some of the following side effects:
Upper respiratory tract infection, increased risk of bleeding. Anaphylaxis, eosinophilic infiltration in the liver site. Dizziness, drowsiness, possible seizures. Palpitations, nosebleeds. Diarrhea, nausea, vomiting, feeling of indigestion, dry mouth. Increased serum ALT, AST, hepatitis including cholestasis, hepatocellular carcinoma, mixed liver injury. Angioedema, urticaria, pruritus, rash, erythema nodosum, appearance of unusual bruising. Joint pain, muscle pain, cramps. Body weakness, malaise, fever, edema.
5. Lukatab drug interactions
Lukatab drug has the potential to interact with some medications, vitamins, herbs you are using. This will cause the active ingredients in the medicine to change the way it works or increase the risk of side effects. Therefore, care should be taken when taking Lukatab with drugs such as Amiodarone, Aprepitant, Barbiturates, Bosentan, Capecitabine, Defirasirox, Dexamethasone....
It is best to inform your doctor about the list of medicines you are using. From here, your doctor may tell you not to take either medicine or change how they are taken.
6. Some notes when using Lukatab
Lukatab has no bronchodilator effect and is not able to relieve acute asthma attacks. For effective asthma control, you can take it in combination with other forms of inhaler, inhaler, or treatment. Talk to your doctor or seek medical attention right away if you experience any unusual symptoms while taking this medication, especially signs of difficulty breathing or a change in behavior. Store the medicine in a cool, dry place at room temperature, away from direct light, out of reach of children. Talk to your doctor before taking Lukatab with medicines that can make asthma worse, such as aspirin or certain nonsteroidal anti-inflammatory drugs. With the above shared information, you have a good understanding of the uses of Lukatab medicine as well as appropriate instructions for use. However, these are only knowledge for reference, absolutely do not arbitrarily use the drug without a prescription from the doctor.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
